Hansa Biopharma AB (HNSBF)
3.65
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Hansa Biopharma Debt to Equity Ratio: -2.947 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | -2.947 |
| June 30, 2024 | -4.371 |
| March 31, 2024 | -2.478 |
| December 31, 2023 | -5.033 |
| September 30, 2023 | -14.58 |
| June 30, 2023 | 4.616 |
| March 31, 2023 | 1.924 |
| December 31, 2022 | 1.265 |
| September 30, 2022 | 2.206 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.0438 |
| Date | Value |
|---|---|
| June 30, 2019 | 0.0295 |
| March 31, 2019 | 0.0009 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.0023 |
| June 30, 2018 | 0.0012 |
| March 31, 2018 | 0.0011 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.0034 |
| June 30, 2017 | 0.003 |
| March 31, 2017 | 0.0023 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.0039 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.0002 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.0002 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.1296 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | |
| June 30, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-14.58
Minimum
Sep 2023
4.616
Maximum
Jun 2023
-0.9697
Average
--
Median
Dec 2019
Debt to Equity Ratio Benchmarks
| Abliva AB | -- |
| Oncopeptides AB | 0.8095 |
| BioInvent International AB | 0.00 |
| BioArctic AB | 0.00 |
| Camurus AB | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 93.30M |
| Total Liabilities (Quarterly) | 125.03M |
| Shareholders Equity (Quarterly) | -31.73M |
| Current Ratio | 2.451 |
| Net Debt Paydown Yield | -1.67% |